Completed × Squamous Cell Carcinoma of Head and Neck × Gastrointestinal × Clear all Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
7 enrolled 14 charts
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Phase 1 Completed
40 enrolled
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Phase 1 Completed
6 enrolled
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Phase 3 Completed
161 enrolled
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1 Completed
89 enrolled
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
KEYVIBE-005
Phase 2 Completed
613 enrolled
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1 Completed
60 enrolled
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Phase 1/2 Completed
25 enrolled 17 charts
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Phase 1 Completed
17 enrolled
ABIMMUNE
Phase 1/2 Completed
54 enrolled
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Phase 2 Completed
175 enrolled 20 charts
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Phase 1 Completed
67 enrolled
Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers
Phase 1 Completed
64 enrolled
PEVOsq
Phase 2 Completed
112 enrolled
ACTolog
Phase 1 Completed
38 enrolled
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1/2 Completed
169 enrolled
VolATIL
Phase 2 Completed
47 enrolled
A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors
Phase 1 Completed
38 enrolled
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Phase 1 Completed
48 enrolled
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Phase 1 Completed
190 enrolled
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
Phase 1/2 Completed
126 enrolled
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Phase 1/2 Completed
12 enrolled
DUET-3
Phase 1 Completed
198 enrolled
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Phase 1 Completed
21 enrolled
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
109 enrolled 25 charts
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Phase 1 Completed
117 enrolled
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
Phase 1 Completed
16 enrolled
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
Phase 2 Completed
30 enrolled 20 charts
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Phase 1 Completed
38 enrolled
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Phase NA Completed
434 enrolled
DUET-4
Phase 1 Completed
78 enrolled
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Phase 1 Completed
13 enrolled 10 charts
DUET-2
Phase 1 Completed
150 enrolled
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
52 enrolled 25 charts
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Phase 1 Completed
174 enrolled 68 charts
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Phase 1/2 Completed
195 enrolled 51 charts
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Phase 1 Completed
40 enrolled
SPICE
Phase 1 Completed
51 enrolled
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Phase 2 Completed
5 enrolled 8 charts
CICAFIX
Phase NA Completed
102 enrolled
ONCODAGE
Phase NA Completed
1,674 enrolled 9 charts
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
Phase 1 Completed
269 enrolled
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Phase 1 Completed
54 enrolled
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Phase 1 Completed
22 enrolled
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
Phase 1 Completed
32 enrolled
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
Phase 1 Completed
8 enrolled
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase 1/2 Completed
175 enrolled